Live Webinar Sessions | April 12, 13, 14, 20, 21, 2022 | 7 pm (CEST) / 1 pm (EDT)
Canon Online Oncology Days | Multimodality Live Webinars
The Canon Online Oncology Days consists of daily interactive webinars, led by world-renowned international experts. The days will provide an online platform for healthcare professionals with an interest in Oncology to connect and learn as we explore innovative imaging and clinical management insights during a series of interactive lectures, practical teaching sessions and real-life clinical case discussions.
Approximately 8.8 million people die of cancer each year, representing every one out of six deaths globally (1). Importantly, cancer incidence is estimated to almost double by 2035 (2). These numbers show the growing burden of cancer on our society in the near future, whether due to increasing age, the risk from lifestyle factors, lack of access to preventative measures and early detection, or lack of access to effective management strategies.
Facing this battle against cancer requires us to work together. To improve the well-being of patients and avoid healthcare system overload, we need to collaborate, not only in the innovation and development of new technologies but also in their implementation and best practices. Canon Medical understands the importance of education and strives to be the ‘’Voice of Oncology’’ by bringing together subject-matter experts from all over the world to share discoveries and insights from research and clinical practice.
This webinar series occurs now in the past. The recordings of each day are now available. Please visit each page to watch the webinars again.
The liver is a common site of metastatic spread, especially tumors from the colon, lung, pancreas and stomach, and in patients with chronic liver disease who are at risk for developing hepatocellular carcinoma. Both CT and MRI have a major role to play in all stages of this disease, from diagnosis, staging, treatment planning to follow-up. During this webinar, experts will guide you through all the possibilities in liver cancer imaging to maximize the image quality and enable clinicians to better treat this challenging disease.
The treatment of patients with liver cancer requires a careful balance of adequate oncologic control and the preservation of both liver function and performance status. Surgery is considered the most effective chance at cure in this patient group, however most patients are not eligible (3). The emerging field of interventional oncology offers the patient treatment options for almost all stages of the disease, all minimal invasive, all image-guided. In this session, we will present how innovative image guidance can offer personalized cancer care.
Lung cancer is the leading cause of death among both men and woman (4). Approximately 70% of patients have advanced disease, therefore only 15% of patients are still alive 5 years after diagnosis (5). The NELSON trial showed that screening with low-dose CT for a high-risk patient group can help diagnose cancer early in these patients (6). Result, increased chances of successful and curable treatment. Our speakers will present the latest developments in lung cancer screening, will advice on how to overcome barriers in clinical implementation and improve access to screening and will share the newest technology in ultra low dose CT.
The increased use of abdominal imaging has resulted in an increase in the number of small renal incidentaloma in recent decades (7). Also most renal cell carcinomas (RCC) are identified as incidental findings (8). Therefore dedicated diagnostic renal imaging is important for characterization of renal tumors to facilitate treatment planning and follow-up. Today’s meeting will center imaging around RCC, from new imaging techniques assessing malignancies, to overcoming technical challenges in thermal ablation treatment, till discussing the best follow-up strategies for RCC.
Prostate cancer is the second most common type of cancer in men. For all men with elevated PSA and clinical suspicion of prostate cancer, MRI has transformed the diagnostic pathway with a frontline position before prostate biopsies (9). The superior sensitivity of MRI also complements the ultrasound-guided biopsy in an innovative fusion technique to target a suspicious lesion. Our speakers will share all the newest developments in the exciting field of prostate cancer together with the benefits of our technology in this field.
The opinions expressed in this material are solely those of the presenter and not necessarily those of Canon Medical Systems. Canon Medical Systems does not guarantee the accuracy or reliability of the information provided herein.
The clinical results, performance and views described in this video/webinar are the experience of the clinician. Results may vary due to clinical setting, patient presentation and other factors. Many factors could cause the actual results and performance of canon Medical’s products to be materially different from any of the aforementioned.
Some products shown might not be available in all regulatory jurisdictions, please consult with your local Canon sales office for availability in your region.
Due to medical device regulatory reasons, not all products/service displayed on this Canon Medical Systems global webpage are available in all countries, regions or markets. Future availability of the products/service cannot also be guaranteed. Please contact your local Canon Medical Systems representative for further details.